Monitoring serum levels of Gal-8 and anti-Gal-8 autoantibodies could be valuable biomarkers to assess the risk of developing more severe AKI or fibrosis, particularly in high-risk patients. The gene discussed is LGALS8; the disease is acute kidney injury.